|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Three-dimensional visualization and virtual reality simulation role in hepatic surgery:Further research warranted显示文摘Artificial intelligence(AI)is the study of algorithms that enable machines to analyze and execute cognitive activities including problem solving,object and word recognition,reduce the inevitable errors to improve the diagnostic accuracy,and decision-making.Hepatobiliary procedures are technically complex and the use of AI in perioperative management can improve patient outcomes as discussed below.Three-dimensional(3D)reconstruction of images obtained via ultrasound,computed tomography scan or magnetic resonance imaging,can help surgeons better visualize the surgical sites with added depth perception.Preoperative 3D planning is associated with lesser operative time and intraoperative complications.Also,a more accurate assessment is noted,which leads to fewer operative complications.Images can be converted into physical models with 3D printing technology,which can be of educational value to students and trainees.3D images can be combined to provide 3D visualization,which is used for preoperative navigation,allowing for more precise localization of tumors and vessels.Nevertheless,AI enables surgeons to provide better,personalized care for each patient. | Faiza Ahmed Vinay Jahagirdar Sravya Gudapati Mohamad Mouchli | 2022 | World Journal of Gastrointestinal Surgery2022，14，7： | 2 |
| 2 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Thl and Th2 cell subsets via distinct signaling pathways显示文摘 | Lee K Gudapati P Dragovic S | 2010 | Immunity2010，32，6： | 1 |
| 3 | Differential requirement ofsignal transducer and activator of transcription-4 ( STAT4 ) andSTAT6 in a thyrotropin receptor-289-adenovirus-induced model ofGraves' hyperthyroidism 显示文摘 | Land J Gudapati P Kaplan MH ef al | 2006 | Endocrinology2006，147，1： | 1 |
| 4 | Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase显示文摘 | Padmanabhan R V Gudapaty R Liener I E | 1955 | Am Rev Respir Dis1955，132，1： | 1 |
| 5 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways显示文摘 | Lee K Gudapati P Dragovic S | 2010 | Immunity2010，32，6： | 1 |
| 6 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Thl and Th2 cell subsets via distinct signaling pathways 显示文摘 | Lee K Gudapati P Dragovic S | 2010 | Immunity2010，32，6： | 1 |
| 7 | Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways显示文摘 | Keunwook Lee Prathyusha Gudapati Srdjan Dragovic Charles Spencer Sebastian Joyce Nigel Killeen Mark A. Magnuson Mark Boothby | 2010 | Immunity2010，，6： | 1 |
| 8 | Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma:A systematic review显示文摘BACKGROUND Despite the use of current standard therapy,the prognosis of patients with unresectable hepatocellular carcinoma(HCC)is poor,with median survival times of 40 mo for intermediate HCC(Barcelona Clinic Liver Cancer[BCLC]stage B)and 6-8 mo for advanced HCC(BCLC stage C).Although patients with earlystage HCC are usually suitable for therapies with curative intention,up to 70% of patients experience relapse within 5 years.In the past decade,the United States Food and Drug Administration has approved different immunogenic treatment options for advanced HCC,the most common type of liver cancer among adults.Nevertheless,no treatment is useful in the adjuvant setting.Since 2007,the multikinase inhibitor sorafenib has been used as a first-line targeted drug to address the increased mortality and incidence rates of HCC.However,in 2020,the IMbrave150 trial demonstrated that combination therapy of atezolizumab(antiprogrammed death-ligand 1[PD-L1])and bevacizumab(anti-vascular endothelial growth factor[VEGF])is superior to sorafenib,a single anti-programmed death 1/PD-L1 antibody inhibitor used as an anti-cancer monotherapy for HCC treatment.AIM To conduct a systematic literature review to evaluate the evidence supporting the efficacy and safety of atezolizumab/bevacizumab as preferred first-line drug therapy over the conventional sorafenib or atezolizumab monotherapies,which are used to improve survival outcomes and reduce disease progression in patients with unresectable HCC and non-decompensated liver disease.METHODS A comprehensive literature review was conducted using the PubMed,Scopus,ScienceDirect,clinicaltrials.gov,PubMed Central,Embase,EuropePMC,and CINAHL databases to identify studies that met the inclusion criteria using relevant MeSH terms.This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and risk of bias(RoB)were assessed using the Cochrane RoB 2 tool and Sevis.RESULTS In the atezolizumab/bevacizumab group,an improvement in overall tumor response,reduction of disease progression,and longer progression-free survival were observed compared to monotherapy with either sorafenib or atezolizumab.Hypertension and proteinuria were the most common adverse events,and the rates of adverse events were comparable to those with the monotherapy.Of the studies,there were two completed trials and two ongoing trials analyzed using high quality and low bias.A more thorough analysis was only performed on the completed trials.CONCLUSION Treatment of HCC with atezolizumab/bevacizumab combination therapy was confirmed to be an effective first-line treatment to improve survival in patients with unresectable HCC and non-decompensated liver disease compared to monotherapy with either sorafenib or atezolizumab. | Faiza Ahmed Jennifer Onwumeh-Okwundu Zeynep Yukselen Maria-Kassandra Endaya Coronel Madiha Zaidi Prathima Guntipalli Vamsi Garimella Sravya Gudapati Marc Darlene Mezidor Kim Andrews Mohamad Mouchli Endrit Shahini | 2021 | World Journal of Gastrointestinal Oncology2021，13，11： | 1 |
| 9 | Monitoring forest plantations using Landsat Thematic Mapper data显示文摘 | COLEMAN T L GUDAPATI L DERRINGTON J | 1990 | Remote Sensing of Environment1990，33，： | 1 |
| 10 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways显示文摘 | LEE K GUDAPATI P DRAGOVIC S | 2010 | Immunity2010，32，6： | 1 |
| 11 | Regulatory interactions of Csr components: the RNA binding protein CsrA activates csrB transcription in Escherichia coli 显示文摘 | Gudapaty S Suzuki K Wang X Babitzke P Romeo T | 2001 | J Bacteriol2001，183，20： | 1 |
| 12 | Flexibility accompanies commitment of memory CD4 lymphocytes derived from IL4 locus-activated precursors 显示文摘 | Adeeku E Gudapati P Mendez-Femandez Y | 2008 | Proc Natl Acad Sci U S A2008，105，27： | 1 |
| 13 | Convergent Approach for Commercial Synthesis of Gefitinib and Erlotinib 显示文摘 | Venkateshappa Chandregowda Gudapati Venkateswara Rao Goukanapa}li Chandrasekara Reddy | 2007 | Organic Process Research & Development2007，11，5： | 1 |
| 14 | Differential requirement of signal transducer and activator of transcription-4 (Stat4) and Stat6 in a thyrotropin receptor-289-adenovirus-induced model of Graves' hyperthyroidism显示文摘 | Land K J Gudapati P Kaplan M H | 2006 | Endocrinology2006，147，： | 1 |
| 15 | Bioprinting of osteochondral tissues:A perspective on current gaps and future trends显示文摘Osteochondral tissue regeneration has remained a critical challenge in orthopaedic surgery,especially due to complications of arthritic degeneration arising out of mechanical dislocations of joints.The common gold standard of autografting has several limitations in presenting tissue engineering strategies to solve the unmet clinical need.However,due to the complexity of joint anatomy,and tissue heterogeneity at the interface,the conventional tissue engineering strategies have certain limitations.The advent of bioprinting has now provided new opportunities for osteochondral tissue engineering.Bioprinting can uniquely mimic the heterogeneous cellular composition and anisotropic extra-cellular matrix(ECM)organization,while allowing for targeted gene delivery to achieve heterotypic differentiation.In this perspective,we discuss the current advances made towards bioprinting of composite osteochondral tissues and present an account of challenges—in terms of tissue integration,long-term survival,and mechanical strength at the time of implantation—required to be addressed for effective clinical translation of bioprinted tissues.Finally,we highlight some of the future trends related to osteochondral bioprinting with the hope of in-clinical translation. | Pallab Datta Aman Dhawan Yin Yu Dan Hayes Hemanth Gudapati Ibrahim T.Ozbolat | 2017 | International Journal of Bioprinting2017，3，2： | 1 |
| 16 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Thl and Th2 cell subsets via distinct signaling pathways 显示文摘 | Lee K Gudapati P Dragovic S | 2010 | Im- munity2010，32，： | 1 |
| 17 | Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease:a prospective,multi-center study显示文摘Background Recent studies have showed that the fine mesh stents are associated with a significant reduction in bothclinical and angiographic re-stenosis of the coronary arteries.To maintain a very satisfactory radio-opacity using thestents,Guidant of the USA has designed a new type of bare metal stents (BMS)-Multi-link (ML) Vision/ML MiniVisionstents.The clinical outcomes of Asian patients with coronary artery disease (CAD) after implanting the Multi-link Vision orMiniVision stent were investigated in this study.Methods An observational,prospective,multi-center,non-randomized post marketing registry was conducted todemonstrate the efficacy of the BMS- ML Vision/ML MiniVision stents.The primary end point of the registry was clinicaltarget lesion revascularization (TLR) at a 6-month follow-up.The major secondary end points included the rate of majoradverse cardiac events (MACE) and serious adverse events (SAE) in hospital and at 6 months;and the rate of clinicalTLR as a function of the type of angina.A total of 429 Asian people with 449 lesions from 14 centers were selected forthis study.The average reference diameter of the lesions was (3.0±0.5) mm,and the mean length was (15.7±5.0) mm.Results The successful rate of the procedure was 99.3%.Twenty-five percent of the lesions were treated by directstenting without pre-dilation.Eighty-six percent of the lesions were implanted with ML Vision stent.After the 6-monthfollow-up,the rate of clinical TLR was 1.4%.The MACE,SAE and target vessel revascularization (TVR) were 6.8%,3.5%and 1.4% respectively.Conclusion The current registry showed the excellent 6-month clinical outcomes of ML Vision/ML MiniVision stents inAsian patients with CAD.Chin Med J 2007;120(12) | XU Ya-wei WEI Yi-dong TANG Kai CHEN Yan-qing LI Wei-ming YU Xue-jing QIN Yong-wen QI Guo-xian QU Peng HOU Yu-qing Ashok Jain Parvez Grant Gudapati Ramesh Basavappa Ramesh Chumpol Piamsomboon Srun Kuanprasert Hyeon-Cheol Gwon Yoon Haeng Cho Haizal Haroon Kamar HUANG Cong-xin | 2007 | Chinese Medical Journal2007，，12： | 1 |
| 18 | Mammalian target of rapamycin protein complex 2 regulates differentiation of Thl and Th2 cell subsets via distinct signaling pathways 显示文摘 | Lee K Gudapati P Dragovie S | 2010 | Immunity2010，32，6： | 1 |
| 19 | Emerging risk factors for cardiovascular diseases:India context显示文摘 | Gupta S Gudapati R Gaurav K | 2013 | India J Endocrinol Metab2013，17，5： | 1 |
| 20 | Emerging risk factors for cardiovascular diseases: Indian context 显示文摘 | Gupta S Gudapati R Gaurav K | 2013 | Indian J Endocrinol Metab2013，17，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员